Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
TriSalus Life Sciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TLSI
Nasdaq
8731
https://trisaluslifesci.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for TriSalus Life Sciences Inc
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives
- Apr 30th, 2024 8:35 pm
TriSalus Life Sciences Inc (TLSI) Q4 and Full Year 2023 Earnings: Revenue Growth Amidst Late ...
- Apr 1st, 2024 1:33 pm
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
- Apr 1st, 2024 12:00 pm
TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting
- Mar 26th, 2024 12:00 pm
TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
- Mar 21st, 2024 12:00 pm
TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results
- Mar 11th, 2024 9:15 pm
TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for "Nelitolimod" as the Nonproprietary Drug Name for SD-101
- Mar 7th, 2024 12:00 pm
TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors
- Feb 29th, 2024 12:00 pm
TriSalus Life Sciences Inc Reports Revenue Growth and Clinical Advancements in Q3 2023
- Nov 14th, 2023 5:27 pm
TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 14th, 2023 1:00 pm
TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call
- Nov 7th, 2023 9:05 pm
Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications
- Nov 4th, 2023 6:25 pm
TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Nov 3rd, 2023 4:00 pm
TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
- Oct 25th, 2023 1:05 pm
TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics
- Sep 6th, 2023 11:00 am
TriSalus Life Sciences First Quarter 2023 Earnings
- Aug 15th, 2023 11:05 am
TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation
- Aug 10th, 2023 8:05 pm
Scroll